var data={"title":"Milrinone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Milrinone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6585?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=milrinone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Milrinone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=milrinone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Milrinone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196740\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Milrinone Lactate Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196770\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Inotrope;</li>\n      <li>\n        Phosphodiesterase-3 Enzyme Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196741\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Inotropic support in heart failure:</b> IV: Loading dose (optional, not recommended by ACCF/AHA 2013 heart failure guidelines; also see <b>&quot;Note&quot;</b>): 50 mcg/kg administered over 10 minutes followed by a maintenance dose titrated according to hemodynamic and clinical response; Maintenance dose: IV infusion: 0.375 to 0.75 mcg/kg/minute; lower initial doses of 0.1 mcg/kg/minute (with final maintenance doses of 0.2 to 0.3 mcg/kg/minute) have also been recommended (HFSA [Lindenfeld 2010]). The ACCF/AHA 2013 heart failure guidelines recommend a maintenance dose of 0.125 to 0.75 mcg/kg/minute (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> When initiating an infusion of 0.5 mcg/kg/minute without a loading dose, significant hemodynamic changes seen at 30 minutes with similar effects on pulmonary capillary wedge pressure and cardiac index seen at 2 and 3 hours, respectively, compared to loading dose regimen (Baruch 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bridge to heart transplantation (off-label use):</b> IV: 0.1 to 0.75 mcg/kg/minute; titrate to optimize clinical condition (Aranda 2003; Bhat 2006; Upadya 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiogenic shock (off-label use):</b> IV: 0.125 to 0.75 mcg/kg/minute (AHA [van Diepen 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative inotropic support in heart transplant recipients (off-label use):</b> IV: 0.375 to 0.75 mcg/kg/minute; use the lowest effective dose and wean as tolerated over the first 3 to 5 days (ISHLT [Costanzo 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46886656\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=milrinone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Milrinone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>PALS Guidelines (cardiac output maintenance and postresuscitation stabilization) (off-label use):</b> Infants, Children, and Adolescents: IV, IO: Loading dose: 50 mcg/kg over 10 to 60 minutes followed by a maintenance infusion of 0.25 to 0.75 mcg/kg/minute (AHA [Kleinman 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196742\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196743\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Manufacturer recommended adjustment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 50 mL/minute/1.73 m<sup>2</sup>: Administer 0.43 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 40 mL/minute/1.73 m<sup>2</sup>: Administer 0.38 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 30 mL/minute/1.73 m<sup>2</sup>: Administer 0.33 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 20 mL/minute/ 1.73 m<sup>2</sup>: Administer 0.28 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 10 mL/minute/1.73 m<sup>2</sup>: Administer 0.23 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 5 mL/minute/1.73 m<sup>2</sup>: Administer 0.2 mcg/kg/minute</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Alternative Dosing Adjustments in Patients with Renal Impairment<sup>1</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">CrCl (mL/min)</p></th>\n          <th colspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Starting dose (mcg/kg/minute)</b></p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>0.375</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>0.5</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>0.75</b></p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;text-align:left;\">\n              <sup>1</sup>Based on expert opinion</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.375</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.125</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.375</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.0625</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.125</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Consider alternative therapy</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.0625</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.125</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Consider alternative therapy</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">0.0625</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td colspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Consider alternative therapy</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20324098\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196720\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mcg/mL (100 mL, 200 mL); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL); 50 mg/50 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mcg/mL (100 mL, 200 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196706\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196723\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV use only. Administer loading dose (optional) undiluted slowly over 10 minutes. Infuse maintenance dose via continuous infusion pump.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472935\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 20 mg in 100 mL (total volume) (concentration: 200 <b>mcg</b>/mL) of D<sub>5</sub>W  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472936\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 200 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196721\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Inotropic support in heart failure:</b> Short-term IV therapy of acutely-decompensated heart failure (HF)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Guideline recommendations:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure</b>: Bridge therapy in stage D HF unresponsive to guideline-directed medical therapy and device therapy in patients awaiting heart transplant or mechanical circulatory support; short-term management of hospitalized patients with severe systolic dysfunction presenting with low blood pressure and significantly depressed cardiac output; long-term management (palliative therapy) in select patients with stage D HF unresponsive to guideline-directed medical therapy and device therapy who are not candidates for heart transplant or mechanical circulatory support (ACCF/AHA [Yancy 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730538\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bridge to heart transplantation; Cardiogenic shock; Palliation of symptoms in end-stage heart failure; Postoperative inotropic support for heart transplant recipients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196778\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Primacor may be confused with Primaxin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196713\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Cardiovascular: Ventricular arrhythmia (ventricular ectopy: 9%, nonsustained ventricular tachycardia: 3%, ventricular tachycardia: 1%, ventricular fibrillation: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Supraventricular cardiac arrhythmia (4%), hypotension (3%), angina pectoris (&le;1%), chest pain (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, atrial fibrillation, bronchospasm, hepatic insufficiency, hypokalemia, injection site reaction, myocardial infarction, skin rash, thrombocytopenia, torsades de pointes, tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196726\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to milrinone or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196710\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Ventricular arrhythmias, including nonsustained ventricular tachycardia and supraventricular arrhythmias, have been reported. Observe closely for arrhythmias in this very high-risk patient population; sudden cardiac death has been observed. Due to the prolonged half-life as compared to other inotropic agents, ventricular or atrial arrhythmias may persist even after discontinuation of milrinone especially in patients with renal dysfunction (Cox 2013; Leier 1998). Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating; may increase ventricular response rate. In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Brozena 2004). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension: Hypotension may occur. Monitor blood pressure closely. Hypotension may be prolonged especially in patients with renal dysfunction (Cox 2013; Leier 1998). Vigorous diuresis may contribute to hypotension; cautious administration of fluids may be required to prevent hypotension. Omitting the bolus dose may decrease the risk of hypotension (Baruch 2001; Cuffe 2002).  If hypotension occurs, consider dose reduction or temporary discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Avoid use in patients with severe obstructive aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction; may aggravate outflow tract obstruction in hypertrophic cardiomyopathy with outflow tract obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; reduction in infusion rate recommended. Hypotension may be prolonged in patients with renal dysfunction (Cox 2013; Leier 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: A facility for immediate treatment of potential cardiac events, including life-threatening ventricular arrhythmias, must be available. Safe and effective use beyond 48 hours (prolonged use) has not been demonstrated. An increased risk of death and hospitalization has been observed with prolonged use in NYHA Class III/IV heart failure patients. Sudden cardiac death has been reported with prolonged use. Continuous electrocardiographic monitoring is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Long-term therapy: According to the ACCF/AHA 2013 heart failure guidelines, long-term use of intravenous inotropic therapy without a specific indication or for reasons other than palliation is potentially harmful (ACCF/AHA [Yancy 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299715\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221703\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9652&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anagrelide: May enhance the adverse/toxic effect of Milrinone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Milrinone may enhance the hypotensive effect of Riociguat.  Management: Riociguat is contraindicated with nonselective phosphodiesterase (PDE) inhibitors and PDE type 5 inhibitors. Other types of PDE inhibitors are not contraindicated, but caution is advised and patients should be monitored for hypotension.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196716\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13334385\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events  have not been observed in animal reproduction studies; however, increased resorption was reported in some studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616344\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if milrinone is present in breast milk. The manufacturer recommends that caution be exercised when administering milrinone to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196718\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Platelet count, electrolytes (especially potassium and magnesium) and fluid status, renal function; ECG, blood pressure, heart rate; infusion site</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If pulmonary artery catheter is in place, monitor cardiac index, stroke volume, systemic vascular resistance, pulmonary capillary wedge pressure and pulmonary vascular resistance.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196709\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A selective phosphodiesterase inhibitor in cardiac and vascular tissue, resulting in vasodilation and inotropic effects with little chronotropic activity. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196725\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV: 5 to 15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub> beta:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants (after cardiac surgery): 0.9 &plusmn; 0.4 L/kg (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (after cardiac surgery): 0.7 &plusmn; 0.2 L/kg (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">After cardiac surgery: 0.3 &plusmn; 0.1 L/kg (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Heart failure (with single injection): 0.38 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Heart failure (with infusion): 0.45 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (minor); majority is not metabolized (Rocci 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants (after cardiac surgery): 3.15 &plusmn; 2 hours (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (after cardiac surgery): 1.86 &plusmn; 2 hours (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Heart failure: 2.3 to 2.4 hours; renal impairment prolongs half-life (Rocci 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Severe heart failure undergoing continuous venovenous hemofiltration (CVVH): 20.1 &plusmn; 3.3 hours (Taniguchi 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (83% as unchanged drug; 12% as 0-glucuronide metabolite); active tubular secretion is a major elimination pathway for milrinone (Rocci 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants (after cardiac surgery): 3.8 &plusmn; 1 mL/kg/minute (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (after cardiac surgery): 5.9 &plusmn; 2 mL/kg/minute (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children (with septic shock): 10.6 &plusmn; 5.3 mL/kg/minute (Lindsay 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">After cardiac surgery: 2 &plusmn; 0.7 mL/kg/minute (Ramamoorthy 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Heart failure: 2.2 to 2.3 mL/kg/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323415\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Milrinone Lactate in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/100 mL 5% (100 mL): $18.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/200 mL 5% (200 mL): $37.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Milrinone Lactate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $7.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/20 mL (20 mL): $11.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL (50 mL): $48.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196728\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Coritrope (ID);</li>\n      <li>Corotrop (AT, CH, CZ, SE);</li>\n      <li>Corotrope (AR, BE, CL, CO, CU, ES, FR, GR, LU, NL, PE, PL, SI, SK, UY, VE);</li>\n      <li>Inovad (ID);</li>\n      <li>Lunan Likang (CN);</li>\n      <li>Milicor (IN);</li>\n      <li>Milron (LK);</li>\n      <li>Nefrisol (LK);</li>\n      <li>Primacor (AU, BR, CR, DO, GB, GT, HK, HN, IL, IN, KR, MT, MX, MY, NI, NZ, PA, PH, SV, TW);</li>\n      <li>Unacor (RO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12595851\"></a>Aranda JM Jr, Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. <i>Am Heart J</i>. 2003;145(2):324-329.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/12595851/pubmed\" target=\"_blank\" id=\"12595851\">12595851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 45, 145.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baruch L, Patacsil P, Hameed A, et al, &ldquo;Pharmacodynamic Effects of Milrinone With and Without a Bolus Loading Infusion,&rdquo; <i>Am Heart J</i>, 2001, 141(2):266-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/11174341/pubmed\" target=\"_blank\" id=\"11174341\">11174341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17117058\"></a>Bhat G. Predictors of clinical outcome in advanced heart failure patients on continuous intravenous milrinone therapy. <i>ASAIO J</i>. 2006;52(6):677-681.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/17117058/pubmed\" target=\"_blank\" id=\"17117058\">17117058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15454175\"></a>Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. <i>J Heart Lung Transplant</i>. 2004;23(9):1082-1086.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/15454175/pubmed\" target=\"_blank\" id=\"15454175\">15454175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation (ISHLT) Guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant</i>. 2010;29(8):914-956.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/20643330/pubmed\" target=\"_blank\" id=\"20643330\">20643330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cox ZL, Calcutt MW, Morrison TB, Akers WS, Davis MB, Lenihan DJ. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. <i>J Cardiovasc Pharmacol Ther</i>. 2013;18(5):433-438.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/23695773/pubmed\" target=\"_blank\" id=\"23695773\">23695773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cuffe MS, Califf RM, Adams KF Jr, et al, &ldquo;Short-Term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2002, 287(12):1541-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/11911756/pubmed\" target=\"_blank\" id=\"11911756\">11911756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cusick DA, Pfeifer PB, and Quigg RJ, &ldquo;Effects of Intravenous Milrinone Followed by Titration of High-Dose Vasodilator Therapy on Clinical Outcome and Rehospitalization Rates in Patients With Severe Heart Failure,&rdquo; <i>Am J Cardiol</i>, 1998, 82(9):1060-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9817482/pubmed\" target=\"_blank\" id=\"9817482\">9817482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Felker GM, Benza RL, Chandler AB, et al, &ldquo;Heart Failure Etiology and Response to Milrinone in Decompensated Heart Failure: Results From the OPTIME-CHF Study,&rdquo; <i>J Am Coll Cardiol</i>, 2003, 41(6):997-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/12651048/pubmed\" target=\"_blank\" id=\"12651048\">12651048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hatzizacharias A, Makris T, Krespi P, et al, &ldquo;Intermittent Milrinone Effect on Long-Term Hemodynamic Profile in Patients With Severe Congestive Heart Failure,&rdquo; <i>Am Heart J</i>, 1999, 138(2 Pt 1):241-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/10426834/pubmed\" target=\"_blank\" id=\"10426834\">10426834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(suppl 3):S876-S908.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leier CV, Binkley PF. Parenteral inotropic support for advanced congestive heart failure. <i>Prog Cardiovasc Dis</i>. 1998;41(3):207-224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9872607/pubmed\" target=\"_blank\" id=\"9872607\">9872607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindsay CA, Barton P, Lawless S, et al. Pharmacokinetics and pharmacodynamics of milrinone lactate in pediatric patients with septic shock. <i>J Pediatr</i>. 1998;132(2)329-334.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9506650/pubmed\" target=\"_blank\" id=\"9506650\">9506650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milrinone lactate [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milrinone Lactate in Dextrose Injection (milrinone lactate in dextrose) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pamboukian SV, Carere RG, Webb JG, et al, &ldquo;The Use of Milrinone in Pretransplant Assessment of Patients With Congestive Heart Failure and Pulmonary Hypertension,&rdquo; <i>J Heart Lung Transplant</i>, 1999, 18(4):367-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/10226902/pubmed\" target=\"_blank\" id=\"10226902\">10226902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar, RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(suppl 3):S768-S786.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramamoorthy C, Anderson GD, Williams GD, Lynn AM. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. <i>Anesth Analg</i>. 1998;86(2):283-289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9459233/pubmed\" target=\"_blank\" id=\"9459233\">9459233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocci ML Jr, Wilson H. The pharmacokinetics and pharmacodynamics of newer inotropic agents. <i>Clin Pharmacokinet</i>. 1987;13(2):91-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/3304772/pubmed\" target=\"_blank\" id=\"3304772\">3304772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevenson LW, &ldquo;Inotropic Therapy for Heart Failure,&rdquo; <i>N Engl J Med</i>, 1998, 339(25):1848-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/9854124/pubmed\" target=\"_blank\" id=\"9854124\">9854124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taniguchi T, Shibata K, Saito S, et al, &ldquo;Pharmacokinetics of Milrinone in Patients With Congestive Heart Failure During Continuous Venovenous Hemofiltration,&rdquo; <i>Intensive Care Med</i>, 2000, 26(8):1089-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/11030165/pubmed\" target=\"_blank\" id=\"11030165\">11030165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15063407\"></a>Upadya S, Lee FA, Saldarriaga C, et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. <i>J Heart Lung Transplant</i>. 2004;23(4):466-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/15063407/pubmed\" target=\"_blank\" id=\"15063407\">15063407</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28923988\"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/28923988/pubmed\" target=\"_blank\" id=\"28923988\">28923988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson TD, Forde MD, Crain AVR, Dombrowski LJ, Joyce MA. Stability of milrinone in 0.45% sodium chloride, 0.9% sodium chloride, or 5% dextrose injections. <i>Am J Hosp Pharm</i>. 1986;43(9):2218-2220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/3766576/pubmed\" target=\"_blank\" id=\"3766576\">3766576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23741058\"></a>Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/milrinone-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S640-S933.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9652 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F196740\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196770\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F196741\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F46886656\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F196742\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F196743\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20324098\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196720\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F196706\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F196723\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472935\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472936\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F196721\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730538\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F196778\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196713\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196726\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196710\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299715\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221703\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196716\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13334385\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616344\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F196718\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196709\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F196725\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323415\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F196728\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9652|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=milrinone-patient-drug-information\" class=\"drug drug_patient\">Milrinone: Patient drug information</a></li><li><a href=\"topic.htm?path=milrinone-pediatric-drug-information\" class=\"drug drug_pediatric\">Milrinone: Pediatric drug information</a></li></ul></div></div>","javascript":null}